Wahl, R. L., Frey, E. C., Jacene, H. A., Kahl, B. S., Piantadosi, S., Bianco, J. A., . . . Swinnen, L. J. (2021). Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 ((111)In)/Yttrium 90 ((90)Y) Ibritumomab Tiuxetan (Zevalin(®)) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels. Cancers (Basel).
Chicago-стиль цитированияWahl, Richard L., et al. "Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 ((111)In)/Yttrium 90 ((90)Y) Ibritumomab Tiuxetan (Zevalin(®)) Theranostic Pair in Patients With Lymphoma At Myeloablative Dose Levels." Cancers (Basel) 2021.
MLA-цитированиеWahl, Richard L., et al. "Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 ((111)In)/Yttrium 90 ((90)Y) Ibritumomab Tiuxetan (Zevalin(®)) Theranostic Pair in Patients With Lymphoma At Myeloablative Dose Levels." Cancers (Basel) 2021.